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Summary
Thrombocytopenia is a common finding in pregnancy, occuring in approximately 7-10% 
of pregnancies. There are diverse etiologies for thrombocytopenia, some of which are unique 
to pregnancy. Overall, about 75% of cases are due to gestational thrombocytopenia, 15-20% 
secondary to hypertensive disorders, 3-4% due to an immune process, and the remaining 1-2% 
made up to rare constitutional thrombocytopenias, infections and malignancies. This review pro-
vides a discussion of the diagnosis and management of the various causes of thrombocytopenia 
in pregnancy.
Key words: thrombocytopenia, pregnancy, gestational thrombocytopenia, immune throm-
bocytopenia, preeclampsia, HELLP syndrome, acute fatty liver of pregnancy, microangiopathic 
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INTRODUCTION 
Thrombocytopenia affects 7-10% of all pregnant women [1]. Most studies report 
a reduction in platelet count during pregnancy, resulting in levels about 10% lower 
than pre-pregnancy level at term. Pregnancy is associated with a physiological fall 
in the platelet count distribution [2]. The mechanisms for this are thought to be 
a combination of dilutional effects and acceleration of platelet destruction across 
the placneta. Pregnant women with thrombocytopenia tend to have fewer bleed-
ing complications than non-pregnant women due to the procoagulant state induced 
by increased levels of fibrinogen, factor VII and von Willebrand factor, suppressed 
fibrinolysis and reduced protein S activity [3]. There are several other pregnancy-
related conditions that can also lead to thrombocytopenia. This review discusses 
the major causes of thrombocytopenia in pregnancy, incuding diagnostic criteria, 
management and prognosis. Thrombocytopenia in pregnancy is a commom reason 
for hematology consultation in one of three situation:
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1. Pre-existing thrombocytopenia
2. Decreasing platelet count or newly discovered thrombocytopenia in preg-
nancy, which may not be related to pregnancy
3. Acute onset of thrombocytopenia in the setting of severe preeclampsia, the 
HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) or AFLP 
(acute fatty liver of pregnancy)
gestational thrombocytopenia
Gestational thrombocytopenia, also known as incidental thrombocytopenia of 
pregnancy, is the most common cause of thrombocytopenia in pregnant women, ac-
counting for approximately 75% of all cases and is not associated with any adverse 
events for either mother or baby [4,5]. It is a diagnosis of exclusion, generally causes 
only mild thrombocytopenia, and occurs in the latter half of pregnancy, from mid-
second or third trimester. Most experts consider this diagnosis less likely if the plate-
let count dips below 70x109/L; the main differential diagnosis at this level or lower is 
ITP. However, there are reports of more severe thrombocytopenia that showed no re-
sponse to steroids, and which resolved postnatally, consistent with gestational throm-
bocytopenia [6]. It is not possible to differentiate between the more severe form of ges-
tational thrombocytopenia, and ITP, as both are diagnoses of exclusion. The degree of 
thrombocytopenia is not generally low enough to increase risk of bleeding at delivery, 
but may compromise the ability to receive epidural anaesthesia. Some suggest that 
a short trial of prednisolone (generally 20 mg/d) may be helpful diagnostically and 
therapeutically when the platelet count is around 50–70x109/L [7]. Gestational throm-
bocytopenia resolved spontaneously within 1-2months after delivery, and the fetus/
newborn baby should not have had thrombocytopenia [4,5,7].
Immune thrombocytopenia
 Primary immune thrombocytopenia (ITP) is an uncommon cause of thrombo-
cytopenia in pregnancy, occurring in between 1 in 1000 and 1 in 10000 pregnant 
women, accounting for approximately 3% of cases of thrombocytopenia in pregnan-
cy [8]. It is a diagnosis of exclusion, although in approximately two-thirds of cases 
the diagnosis is already established before pregnancy, allowing the opportunity for 
prepregnancy counselling. The thrombocytopenia in ITP is predominantly caused 
by antibodies that are specific to platelet surface glycoproteins and which bind to 
the platelets in the maternal circulation, resulting in immune-mediated platelet de-
struction. Recent research suggests there is also suppression of platelet production. 
The antibodies can cross the placenta and cause fetal thrombocytopenia.
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Despite good understanding of the pathological mechanisms, there are no specif-
ic diagnostic tests for ITP. Although platelet antibodies can be demonstrated in these 
cases, the tests lack sensitivity and specificity and, therefore, the diagnosis of ITP is 
one of exclusion. Careful history, examination and laboratory specimens are helpful 
in excluding other causes of thrombocytopenia. As stated, the main difficulty is dif-
ferentiation from gestational thrombocytopenia. However, this is not often a problem 
clinically, since no treatment is required for either condition when the platelet count is 
>70–80x109/L. It is unusual to have a count of <70x109/L in gestational thrombocytope-
nia. However, unlike gestational thrombocytopenia, ITP can cause thrombocytopenia 
in the newborn infant, though this is rare, particulary in mild ITP.
The clinical management of the pregnant woman with ITP requires close consul-
tation between the obstetrician and the hematologist. The decision to treat thrombo-
cytopenia is determined by the patient’s symptoms and the level of thrombocytope-
nia [9,10]. The goal of therapy is to prevent bleeding, and treatment is generally not 
required in patients with platelet counts greater than 20x109/L to 30x109/L if they are 
not symptomatic. If the patient is asymptomatic and platelet count is above 20x109/l, 
close monitoring is recommended. The frequency of serial platelet count monitoring 
should be increased as term approaches or thrombocytopenia worsens. Treatment 
should also be considered if platelet counts are below 30x109/L in the third trimester 
due to the potential for imminent delivery. Platelet transfusion alone is not helpful 
due to the quick destruction of transfused platelets as evidenced by a poor incre-
ment in the post-transfusion platelet count. Primary treatment options for maternal 
ITP are corticosteroids and intravenous immunoglobulin (IVIG). 
The typical starting dose is 1 mg/kg of prednisone based on the prepregnancy 
weight with a quick taper once a response is achieved. Glucocorticoids can cause 
several unique toxicities in pregnancy, such as gestational diabetes and pregnancy-
induced hypertension. These agents may also be associated with premature rupture 
of fetal membranes and placental abruption [9]. Hence, they should be used spar-
ingly with the minimal effective doses employed. IVIG may be used as first line or 
in steroid resistant patients. IVIG can be used (1g/kg in a single or 2 divided doses), 
either alone or in combination with small doses of prednisone, to maintain safe 
platelet counts. The therapeutic response to IVIG is attributable to several differ-
ent immunological mechanisms, including blockage of splenic macrophages [10]. 
In life-threatening bleeding platelet transfusion plus combination treatment with 
IVIG and a pulse of methyl prednisolone is necessary. Intravenous anti-D could 
be considered in non-splenectomized Rh positive patients who are resistant to ste-
roids and IVIG. Experience is limited in pregnant women, the response rates are 
comparable to IVIG [1,10]. Therefore this is best avoided until further safety data 
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ia available. Splenectomy may induce a remission and has been reported to be as-
sociated with few complications if performed during the second trimester, when 
risk of anesthesia to the fetus are minimal and uterine size will not complicate the 
procedure [11]. Rituximab is increasingly being used to treat ITP in non-pregnant 
women. Limited data are available for rituximab in pregnancy, and the use of this 
drug for pregnancy-associated ITP cannot be recommended because of its potential 
for crossing the placenta [12]. Other agents used in the treatment of the non-preg-
nant women with ITP, such as cytotoxic and immunosupressive agents, are discour-
aged during pregnancy due to the potential teratogenic effects. The thrombopoietin 
receptor agonists such as romiplostim and eltrombopag stimulate platelet produc-
tion by binding to the platelet thrombopoietin receptor and have been approved for 
treatment of chronic ITP in adults. These agents should be avoided in pregnancy 
as there is no information on the reproductive effects [1,10,13]. Episodes of severe 
bleeding are rare, even with very low platelets. The most common complication in 
the peripartum time period relates to the use of regional anesthesia during delivery.
Vaginal delivery is the preferred method of delivery. Cesarean section should be 
reserved for obstetric indications only. The risk for intracranial hemorrhage in in-
fants of women with ITP is very low. In addition, vaginal delivery does not increase 
the risk of intracranial hemorrhage compared to cesarean section [14,15]. Regional 
anesthesia during labor in thrombocytopenic patients is controversial due to the 
increased risk of epidural hematoma; the decision regarding epidural anesthesia 
should be made in consultation with the anesthesiologist [15]. Thrombocytopenia 
in infants born to women with ITP is uncommon. Fortunately, 90% of these infants 
will not have significant thrombocytopenia. Only 10% develop more severe throm-
bocytopenia with platelet counts below 50x109/L and platelet counts below 20x109/l 
occur in approximately 4% of infants. The platelet count should be measured in the 
neonate at birth and for several days following delivery as fetal platelet counts con-
tinue to drop after delivery with nadir 1 to 2 days [15,16]. 
Preeclampsia 
Preeclampsia is the second most frequent cause of thrombocytopenia developing 
in the late second or third trimester, accounting for 21% of cases of thrombocytopenia 
at the time of delivery [16]. It is defined by new onset hypertension with ≥140 mmHg 
systolic or ≥90 mmHg diastolic blood pressure after 20 weeks’ gestation together with 
proteinuria (≥ 0.3 g protein in a 24-hour specimen) [17]. Approximately 15%-25% of 
women with gestational hypertension will develop preeclampsia. In some women, the 
signs of preeclampsia can present as late as 4-6 weeks postpartum. There are very few 
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data on the proportion of preeclampsia that occurs antepartum versus postpartum, 
but reports of the incidence of new-onset postpartum hypertension or preeclampsia 
range from 0.3% to 27.5% [18]. There is increased endothelial cell activation leading to 
the activation of platelets and the coagulation cascade.
The diagnosis of eclampsia is made with the onset of seizures that cannot be at-
tributed to other causes in a woman with preeclampsia. Thrombocytopenia may be 
the only initial manifestation of preeclampsia. Platelet counts <50 x109/L occur in <5% 
of preeclamptic women [19]. Intravascular hemolysis resulting from red cell fragmen-
tation can accompany severe preeclampsia but is usually not a prominent feature. 
Coagulation abnormalities are unlikely if the count is >100 x 109/l. Transaminases and 
LDH levels may be elevated, although less than seen in the HELLP syndrome.
HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome
The HELLP syndrome is often considered to be a variant of preeclampsia. It is 
serious complication specific to pregnancy, affects 0.5-0.9% of all pregnancies and 
develops in 10% of patients with preeclampsia [20]. The HELLP syndrome is charac-
terized by hemolysis, elevated liver enzymes and low platelets. The pathophysiology 
is similar to preeclampsia, with endothelial damage and release of tissue factor and 
coagulation activation. A recent study identified mutations in genes that regulate 
the alternative complement system, suggesting that excessive complement activation 
may be involved in pathogenesis similar to atypical hemolytic uremic syndrome [21]. 
The criteria for HELLP syndrome vary among studies, but generally include micro-
angiopathic hemolytic anemia, increased liver enzymes and thrombocytopenia with 
platelet counts less than 100x109/L [20]. HELLP syndrome may represent advanced 
preeclampsia, although 15-20% presenting with HELLP do not have antecedent hy-
pertension and proteinuria. It occurs predominantly in the third trimester between 
28-36 weeks of gestation, although a small percentage can occur prior to 27 weeks 
[22]. HELLP syndrome, like preeclampsia, can occur postpartum. Unlike preeclamp-
sia, HELLP is more common in multiparous women. Patients present with abdomi-
nal pain and tenderness in the epigastrium and right upper quadrant, which may be 
accompanied by nausea, vomiting and malaise. Hypertension and proteinuria are 
present in 85% of cases. Generalized edema precedes the syndrome in more than half 
the cases [22]. Although thrombocytopenia is present, bleeding is not typical. HELLP 
can be difficult to differentiate from preeclampsia; however a typical patient typical-
ly does have hypertension and proteinuria. Thrombocytopenia is much more severe 
in HELLP than in preeclampsia. Thrombotic microangiopathies causing thrombocy-
topenia are also difficult to distinguish from HELLP.
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The overall approach to management of either of these syndromes involves 
medical stabilization of the patient, followed by delivery of the fetus. Because most 
cases of preeclampsia and HELLP develop after 34 weeks of gestation, by which 
time the fetal lung has adequately matured, immediate delivery is considered to 
be the definite treatment. Therapy in the setting of severe thrombocytopenia and 
bleeding may require platelet transfusion; however, since the mechanism of throm-
bocytopenia in these cases is accelerated platelet destruction, survival of transfused 
platelets is short. In the absence of other complications, such as renal dysfunction or 
DIC, platelet counts tend to rise between the fourth and the sixth day post-partum. 
When severe laboratory abnormalities persist after 72 hours, the use of plasma ex-
change and glucocorticoids can be considered. For pregnancies fewer than 34 weeks 
gestation, where there is no maternal and fetal distress, glucocorticoids are recom-
mended to accelerate fetal pulmonary maturity followed by delivery in 48 hours. 
Observation alone without a plan for delivery is not generally recommended be-
cause the condition rarely reverses until delivery of the baby [20,22]. 
Acute fatty liver of pregnancy (AFLP)
AFLP is a rare, serious disorder that presents in the third trimester or post-
partum with an approximate incidence of 1 in 7000 to 1 in 20,000 deliveries [23]. 
It is more common with multiple gestations and possibly in women who are un-
derweight. The disease is always present before delivery, although it is not always 
diagnosed prior to delivery. Usually presents with nausea, vomiting, malaise, right 
upper quadrant pain, and cholestatic liver dysfunction. Laboratory findings include 
low platelet count, prothrombin time, low fibrinogen, and low antitrombin levels in 
addition to raised bilirubin levels. This results in a clinical picture similar to DIC; 
however, in AFLP, the values are abnormal not due to consumption of the cloting 
factors but rather to decreased production by the damaged liver. Some cases of acute 
fatty liver, as well as HELLP, may be associated with fetal mitochondrial fatty acid 
oxidation defects, most commonly due to deficiency of long-chain 3-hydroxyacyl co-
enzyme A dehydrogenase. Treatment involves supportive care with blood product 
support for the coagulopathy [23].
Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syn-
drome (HUS) 
Thrombotic thrombocytopenic purpura (TTP) and the hemolytic uremic syn-
drome (HUS) are characterized by microangiopathic hemolytic anemia and throm-
bocytopenia. The incidence od TTP-HUS among all pregnancies is only 1 in 25 000. 
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TTP-HUS that initially occurred in nonpregnant women has relapsed during a 
subsequent pregnancy and recurrent TTP-HUS has developed during successive 
pregnancies. The time of onset of TTP-HUS in pregnancy is variable [24]. TTP is 
characterized by a pentad of findings that include microangiopathic hemolytic ane-
mia, thrombocytopenia, neurologic abnormalities, fever and renal dysfunction. The 
clinical manifestations of HUS are similar, though often predominated by renal ab-
normalities as opposed to neurologic abnormalities in patients with TTP.
The pathogenesis of TTP involves the congenital or acquired deficiency of the 
vWF cleaving protein, also known as ADAMTS1, (a disintegrin and metallopro-
teinase with a thrombospondin type 1 motif, member 13 – von Willebrand factor 
cleaving protein) [25]. In the absence of ADAMTS13, ultra large multimers of vWF 
(ULVWF) released from endothelium are not cleaved appropriately, and cause spon-
taneous platelet aggregates in conditions of high shear, such as in the microvascula-
ture of the brain, heart and kidneys. Congenital TTP is due to an inherited deficien-
cy of ADAMTS13, but acquired immune TTP is due to the reduction of ADAMTS13 
by autoantibodies directed against ADAMTS13 [25].
Diagnosis can be difficult, as there is clinical overlap with haemolytic uraemic 
syndrome (HUS), autoimmune disease and a spectrum of pregnancy-related prob-
lems. The diagnosis is based upon the clinician's judgment after considering the 
history, physical examination, and laboratory findings. The coagulation screen is 
normal in TTP, and may help to differentiate it from other microangiopathies.
Hemolytic uremic syndrome (HUS) is a more heterogeneous disease. The most 
common form of HUS (90% of cases) is caused by an infection with Shiga-toxin 
producing Escherichia coli (particularly types O157:H7 and O104:H4). Atypical HUS 
is the most common form of HUS in pregnancy and has been associated with con-
genital defects of the alternative pathway of the complement system [24].
Early diagnosis of TTP/HUS is essential to institute treatment promptly because 
most fatal events occur within 24 hours from presentation in untreated subjects [24, 
26]. Any patient with thrombocytopenia and microangiopathic hemolytic anemia in 
the absence of any obvious precipitating condition should be classified as TTP/HUS.
Despite the difficulties of diagnostic certainty, plasma exchange needs to be 
commenced urgently and good clinical judgement is required. By using this proce-
dure antibodies are removed and 1–1.5 L fresh frozen plasma containing the absent 
enzyme is infused daily until the platelet count is normal and the lactate dehydro-
genase level is reduced. The number of treatments required is extremely variable 
and high doses of steroids may be indicated. Steroids have been used, often in con-
junction with plasmapheresis. However, steroids are less effective than plasmapher-
esis (25% response rate). Other therapies include immunosupresive agents, splenec-
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tomy for TTP, and hemodialysis for HUS. Rituximab, a monoclonal antibody against 
CD20, has been used successfully when improvement has been slow. About 25% of 
women affected experience recurrent episodes. In the rare congenital cases, infu-
sion of fresh frozen plasma rather than plasma exchange is carried out, since these 
women do not have antibodies. Platelet transfusions are contraindicated because 
they are known to precipitate or exacerbate central nervous symptoms. A central 
line should be placed without platelet support, as the risk of bleeding is low in this 
condition. Delivery does not generally cause resolution of TTP-HUSthere is anec-
dotal evidence that it may do so in selected patients. However, termination of the 
pregnancy is usually not required. There has been no report of transmission of TTP 
to the infant. Intrauterine fetal death may occur due to placental infarction caused 
by thrombosis of the decidual arterioles conditions.
In conclusion, thrombocytopenia during pregnancy is common, it is not fre-
quently severe. Diagnosis is dependent on timing of its onset, severity of the throm-
bocytopenia, and the association with other abnormalities. Isolated mild thrombo-
cytopenia may require observation alone and present no risk to the mother or fetus. 
More sever thrombocytopenia or that associated with hypertension, liver abnor-
malities, neurologic or renal abnormalities, requires consideration of the diverse 
pathophysiologic mechanisms. Management of pregnant women with thrombocy-
topenia requires a multidisciplinary approach with a close collaboration between 
the hematologist and the obstetrician.
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Sažetak
Trombocitopenija u trudnoći
Trombocitopenija se često susreće u trudnoći, pojavljuje se u oko 7-10% trudnoća. Etiologija 
u većini slučajeva ostaje nepoznata, ali neki od čimbenika su jedinstveni za trudnoću. Općenito, 
75% slučajeva otpada na gestacijsku trombocitopeniju, 15-20% su sekundarne trombocitopenije 
u sklopu hipertenzivne bolesti, 3-4% zbog imunoloških bolesti, a preostalih 1-2% su rijetke kon-
stitucionalne trombocitopenije, vezane uz infekcije i zloćudne bolesti. U ovom članaku rasprav-
lja se o dijagnostičkim postupcima i terapijskom pristupu u trombocitopeniji u trudnoći obzirom 
na etiološke čimbenike.
Ključne riječi: trombocitopenija, trudnoća, gestacijska trombocitopenija, imuna tromboc-
itopenija, preeklampsija, HELLP sindrom, akutna masna jetra u trudnoći, mikroangiopatska 
hemolitička anemija i trombocitopenija
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